Vasculitis & polymyalgia rheumatica
Mortality in polymyalgia rheumatica: a 38-year prospective population-based cohort study from Southern Norway
Main finding · All-cause mortality, overall SMRResult — go to the resultSMR 0.97 95% CI 0.85–1.09Authors' conclusion
In this comprehensive long-term follow-up study with nearly complete data on mortality, isolated PMR was not associated with increased mortality, reinforcing the view that it does not confer a higher mortality risk.
Study context
- Population
- Incident PMR and biopsy-proven GCA, Aust-Agder County, Norway, 1987–1997; followed to December 31st, 2024mean follow-up 13.7 years
- Participants
- 337 participants
- Exposure
- Isolated PMR vs matched population comparators
- Isolated PMRn = 274
- GCAn = 63
- Outcome
- All-cause mortality in isolated PMR (SMR)
Methodological detailsmatched by gender, age at inclusion and residency with 15 population comparators, standard mortality ratios and Kaplan-Meier method
- Matched by gender, age at inclusion and residency with 15 population comparators
- Standard mortality ratios and Kaplan-Meier method
Main finding
All-cause mortality, overall SMR
Standard mortality ratios (SMR)
0.97
95% CI 0.85–1.09
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SMR (95% CI) |
|---|---|
| All-cause mortality in isolated PMR, men (subgroup)Isolated PMR vs Population comparators | 0.77 (0.62–0.95) |
| All-cause mortality in isolated PMR, women (subgroup)Isolated PMR vs Population comparators | 1.11 (0.95–1.28) |
| All-cause mortality in GCA, overall SMRGCA vs Population comparators · with no gender difference | 1.10 (0.85–1.40) |
Deceased by end of study (all patients)
- Deceased by end of study, all patients
- 96.4%
Original publication
Mortality in polymyalgia rheumatica: a 38-year prospective population-based cohort study from Southern Norway. Arthritis Res Ther. Published 21 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →